^
Association details:
| Biomarker: | ALK rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up
Published date:
07/28/2019
Excerpt:
For three ALK-rearranged patients, ipilimumab PFS was 24.1 months.
Trial ID:
